I've started selegiline about a month ago, taking 1-2 mg as deprenyl
citrate with the trade name Cyprenil. I really like its effects on me
(I'm a 44-year-old male). I have noticed a welcome increase in
motivation and confidence. Selegiline really enhanced the effect of
phenlyalanine for me on the first occasion I took them together, but
not quite so much when I tried it a week later. I generally take
phenylalanine a few times a month.

I understand that BPAP is not a strong MAO inhibitor, unlike
selegiline which is a selective MAO-B inhibitor at low doses and
starts inhibiting MAO-A at higher ones, and that BPAP is potentially
safer for this reason according to Knoll
(http://www.lmreview.com/articles/Interview_DrKnoll.html). Knoll seems
to indicate that the lifespan enhancing quality of selegilene are due
to its "mesencephalic enhancer" property rather than its MAO
inhibition (http://pubmed.gov/12697274).

From http://pubmed.gov/10588928, "In rats (-)BPAP significantly
enhanced the activity of the catecholaminergic and serotoninergic
neurons." I would be interested in hearing any anecdotal reports from
those (few, apparently) using BPAP, which is a supplement that I am
considering. I'm curious about how people subjectively experience
BPAP's effects given that it also acts on the serotonin pathway,
unlike deprenyl.

The Wikipedia article on selegilene says that the "stimulatory effect
on locomotor activity and dopamine synthesis may be contributed to by
the action of l-methamphetamine". I'm not sure what part of the
positive benefits on drive and self-confidence of selegiline come from
it being metabolized to l-methamphetamine. I'm hoping that BPAP would
do the same thing even though it doesn't metabolize to l-methamphetamine.

In choosing what to supplement, another concern is whether to take
both deprenyl and BPAP or just one of the two. My hope with BPAP is
that the lack of MAO inhibition translates to less uncertainty in
finding the sweet spot of the U-curve and thus greater safety.

By the way, the full text of
"(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective
enhancer of the impulse propagation mediated release of catecholamines
and serotonin in the brain" (1999) is viewable from nature.com:
http://www.nature.com/bjp/journal/v128/n8/full/0702995a.html.

Stephen Boulet